vinyl 2-(phenylthio)acetate | 1173105-42-4

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: vinyl 2-(phenylthio)acetate
• 英文别名: Ethenyl 2-phenylsulfanylacetate；ethenyl 2-phenylsulfanylacetate
• CAS: 1173105-42-4
• 化学式: C₁₀H₁₀O₂S
• 分子量: 194.254
• InChiKey: PPVJFAWETPAUDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  51.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  苏合香醇 、 vinyl 2-(phenylthio)acetate 在 Candida antarctica lipase B 作用下， 以 乙醚 为溶剂， 反应 4.0h， 以48%的产率得到1‑phenylethyl 2‑(phenylthio)acetate
  参考文献：
  名称：

  Lipase-mediated enantioselective acylation of alcohols with functionalized vinyl esters: acyl donor tolerance and applications

  摘要：

  Enzymatic acylation is commonly used for the kinetic resolution of alcohols and amines. The simple acyl group introduced during the enzymatic reaction is Usually removed or replaced by another group. Retention of more complex acyl moieties as part of the target structures would be a more efficient strategy. We have studied the enantioselective acylation of a model alcohol substrate, 1-phenylethanol, with vinyl esters bearing various functionality on the acyl moieties in the presence of three lipases (Candida antarctica, Candida rugosa and Burkholderia cepacia) frequently used in organic synthesis. C. antarctica lipase is the most versatile lipase for this type of biotransformations. We applied this strategy to the synthesis of a protein kinase C ligand and a natural product, phoracantholide. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2009.03.027
• 作为产物：
  描述：

  乙酸乙烯酯 、 苯硫基乙酸 在 氢氧化钾 、 palladium diacetate 作用下， 以44%的产率得到vinyl 2-(phenylthio)acetate
  参考文献：
  名称：

  Lipase-mediated enantioselective acylation of alcohols with functionalized vinyl esters: acyl donor tolerance and applications

  摘要：

  Enzymatic acylation is commonly used for the kinetic resolution of alcohols and amines. The simple acyl group introduced during the enzymatic reaction is Usually removed or replaced by another group. Retention of more complex acyl moieties as part of the target structures would be a more efficient strategy. We have studied the enantioselective acylation of a model alcohol substrate, 1-phenylethanol, with vinyl esters bearing various functionality on the acyl moieties in the presence of three lipases (Candida antarctica, Candida rugosa and Burkholderia cepacia) frequently used in organic synthesis. C. antarctica lipase is the most versatile lipase for this type of biotransformations. We applied this strategy to the synthesis of a protein kinase C ligand and a natural product, phoracantholide. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2009.03.027

文献信息

• [EN] CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING<br/>[FR] FORMES CRISTALLINES D'UN INHIBITEUR DE LYSYL OXYDASE DE TYPE 2 ET LEURS PROCÉDÉS DE FABRICATION
  申请人：PHARMAKEA INC

  公开号：WO2018048943A1

  公开（公告）日：2018-03-15

  Described herein are crystalline forms of pharmaceutically acceptable salts of the lysyl oxidase-like 2 (LOXL2) inhibitor (3-(4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yloxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone. Also described are methods of making the LOXL2 inhibitor, pharmaceutical compositions and medicaments comprising the LOXL2 inhibitor, and methods of using the LOXL2 inhibitor in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述了赖氨酸氧化酶样2（LOXL2）抑制剂（3-（4-（氨甲基）-6-三氟甲基吡啶-2-氧基）苯基）（（3R,4R）-3-氟-4-羟基吡咯烷-1-基）的药用盐的晶体形式。还描述了制备LOXL2抑制剂的方法，包含LOXL2抑制剂的药物组合物和药物，以及在治疗与LOXL2活性相关的状况、疾病或障碍中使用LOXL2抑制剂的方法。
• Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
  申请人：PHARMAKEA, INC.

  公开号：US10774069B2

  公开（公告）日：2020-09-15

  Described herein are crystalline forms of pharmaceutically acceptable salts of the lysyl oxidase-like 2 (LOXL2) inhibitor (3-(4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yloxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone. Also described are methods of making the LOXL2 inhibitor, pharmaceutical compositions and medicaments comprising the LOXL2 inhibitor, and methods of using the LOXL2 inhibitor in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述了赖氨酰氧化酶样2（LOXL2）抑制剂（3-(4-(氨基甲基)-6-(三氟甲基)吡啶-2-基氧基)苯基)((3R,4R)-3-氟-4-羟基吡咯烷-1-基)甲酮的药学上可接受的盐的结晶形式。还描述了制造LOXL2抑制剂的方法，包含LOXL2抑制剂的药物组合物和药物，以及使用LOXL2抑制剂治疗与LOXL2活性相关的病症、疾病或紊乱的方法。
• CRYSTALLINE FORMS OF A LYSYL OXIDASE-LIKE 2 INHIBITOR AND METHODS OF MAKING
  申请人：Pharmakea, Inc.

  公开号：EP3510023A1

  公开（公告）日：2019-07-17